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Abstract
Background: The new Global Obstructive Lung Disease (GOLD) guidelines advice to focus
treatment in Chronic Obstructive Pulmonary Disease (COPD) on improvement of functional state,
prevention of disease progression and minimization of symptoms. So far no validated
questionnaires are available to measure symptom and functional state in daily clinical practice. The
aim of this study was to develop and validate the Clinical COPD Questionnaire (CCQ).
Methods: Qualitative research with patients and clinicians was performed to generate possible
items to evaluate clinical COPD control. Thereafter, an item reduction questionnaire was sent to
77 international experts. Sixty-seven experts responded and the 10 most important items, divided
into 3 domains (symptoms, functional and mental state) were included in the CCQ (scale: 0 = best,
6 = worst).
Results: Cross-sectional data were collected from 119 subjects (57 COPD, GOLD stage I-III; 18
GOLD stage 0 and 44 (ex)smokers). Cronbach's α was high (0.91). The CCQ scores in patients
(GOLD 0-III) were significantly higher than in healthy (ex)smokers. Furthermore, significant
correlations were found between the CCQ total score and domains of the SF-36 (ρ = 0.48 to ρ =
0.69) and the SGRQ (ρ = 0.67 to ρ = 0.72). In patients with COPD, the correlation between the
CCQ and FEV1%pred was ρ =-0.49. Test-retest reliability was determined in 20 subjects in a 2-
week interval (Intra Class Coefficient = 0.94). Thirty-six smokers with and without COPD showed
significant improvement in the CCQ after 2 months smoking cessation, indicating the
responsiveness of the CCQ.
Conclusion: The CCQ is a self-administered questionnaire specially developed to measure clinical
control in patients with COPD. Data support the validity, reliability and responsiveness of this
short and easy to administer questionnaire.
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Introduction
Chronic obstructive pulmonary disease (COPD) is one of
the leading causes of morbidity and mortality in industri-
alized and developing countries. The mortality rate for
COPD is rising and COPD will probably become the third
leading cause of death by the year 2020 [1,2]. A study by
Feenstra and coworkers showed that there will be an una-
voidable increase in the burden of COPD between now
and 2015 that is independent from the success of smoking
cessation campaigns [3]. In recent years, a great deal of at-
tention has been paid to developing and validating quali-
ty of life questionnaires for patients with COPD in order
to identify and treat the problems that are most important
to these patients [4–6]. Health-related quality of life ques-
tionnaires were developed to help identify and treat the
functional problems that are most important to patients
with COPD. These questionnaires are now being used ex-
tensively in clinical trials [7–9].
Health-related quality of life has been defined as the 'func-
tional effect of an illness and its consequent therapy upon
a patient, as perceived by the patient' and therefore these
questionnaires tend to focus only on the impairments that
are important to patients, and often correlate poorly with
the clinical status of the airways (e.g. airway inflammation
and obstruction) [10]. More recently, the GOLD guide-
lines have identified the goals of treatment for patients
with COPD. These include the patients' goals of improved
exercise tolerance and emotional function (health-related
quality of life) and also important clinical goals such as
prevention of disease progression and minimization of
symptoms [11]. Currently, however, there are no instru-
ments that incorporate both the clinicians' and patients'
goals as identified by the GOLD committee.
The incentive for the development of a practical health
status instrument, the Clinical COPD Questionnaire
(CCQ) arose from routine clinical management of COPD
in general practice where it was recognized that clinicians
require a simple tool that will help them to identify not
only the clinical status of the airways but also activity lim-
itation and emotional dysfunction in the patient. It was
also thought that such an instrument would encourage
clinicians not to focus entirely on the state of the airways
and to become more conscious of the patients' functional
needs. Although the CCQ has been developed primarily
for use in clinical practice, it was recognized that a simple,
carefully developed and validated instrument would also
be useful in clinical trials and other research studies to
evaluate the adequacy of clinical management and to as-
sess the effect of interventions on the overall goals of the
GOLD guidelines.
The methods used to develop the CCQ were adapted from
those used to develop both quality of life questionnaires
[12] and clinical status questionnaires. Clinical control of
COPD was defined to include "The full range of clinical
impairment that patients with COPD may experience as a
result of their disease" [13]. The initial specifications for
the CCQ identified that the questionnaire should not
only contain the symptoms that physicians consider to be
the most important for estimating the clinical status of the
airways but also the functional impairments that are most
important to patients (physical and emotional function).
Therefore, both clinicians and patients played an impor-
tant role in determining the items that should be included
in the CCQ.
After the development and pretesting of the question-
naire, the psychometric properties of the CCQ were eval-
uated. This article describes the development and
validation of the CCQ.
Development of the CCQ
Item generation
Interviews and focus group discussions with COPD pa-
tients were conducted to collect potentially relevant items
for the CCQ. The disease severity of patients in the focus
groups varied from mild to severe. Two focus group dis-
cussions were conducted in The Netherlands and one in
the United Kingdom including a total number of 34 pa-
tients. Twelve individual interviews were conducted in
The Netherlands. Interviews and focus group discussions
were transcribed. The transcripts were read by a team that
included the authors TM, SS and two independent re-
searchers. Emergent themes were discussed and used to
generate items. Results of the Dutch interviews and focus
groups were analyzed in Dutch and then translated in
English for further development of the CCQ. To ensure
that all possible items were included, we also reviewed
other COPD questionnaires, identified treatment goals
from international guidelines and consulted a number of
clinicians involved in the treatment of patients with
COPD. A list of sixteen items divided into 3 domains that
might be used by clinicians to assess clinical COPD con-
trol was generated by the team.
Item reduction
Subjects and methods
Seventy-seven international clinicians and experts in the
field of COPD management were asked to participate in
the item reduction phase. Each expert or clinician was sent
a list of the sixteen items identified in the item generation
phase and asked to rank them in order of importance and
to score the importance of each item for the assessment of
clinical COPD control (1=extremely important,
5=useless).Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/13
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Results
Sixty-seven questionnaires were returned (87%). The data
of sixty respondents could be used for data analysis.
Domains
The domains functional state (ranking 1; importance 1)
and symptoms (ranking 2; importance 1) were considered
the most important domains. However, the experts con-
sidered the domain mental state (ranking 3; importance
2) also important to evaluate clinical COPD control.
Symptom domain
Shortness of breath at rest (ranking 1; importance 1) and
during exercise (ranking 2; importance 1) were considered
to be the most important items, followed by coughing
(ranking 4; importance 2), sputum production (ranking
5; importance 2), nightly shortness of breath (ranking 5;
importance 3) and fatigue (ranking 5; importance 3).
Wheezing (ranking 6; importance 3) and shortness of
breath due to emotional distress (ranking 8; importance
4) were ranked as least important items by the clinical
experts.
Mental state
Fear of the next exacerbation (ranking 2; importance 2),
depression (ranking 2; importance 2) and fear (in gener-
al) (ranking 2; importance 2) were considered as the most
important items, followed by bad mood (ranking 4; im-
portance 3) and cognition (ranking 4; importance 3).
Functional state
In the item reduction questionnaire a subdivision in three
standardized activities was proposed. Ninety percent of
the respondents indicated that the activities covered im-
portant issues of daily life for patients. Nearly 40% of the
respondents had remarks regarding the classification and
the description of the subdivision. It was often mentioned
that social activities do not fit in the row of strenuous and
moderate activities. Respondents suggested to add a cate-
gory of light activities or daily activities. Another remark
concerned the usefulness of the activity hobbies. It was
suggested not to include hobbies in the functional state
domain because the amount of activity can differ between
different hobbies.
Clinical COPD Questionnaire
The symptom domain and the functional state domain
were considered extremely important by the experts and
were nearly equally ranked. The mental state domain was
ranked third and was considered very important. In order
to meet the opinion of the experts, we decided to include
the four highest scoring items in the symptom domain,
four items in the functional state domain and the two
highest scoring items in the mental state domain.
Administration of the CCQ
To meet the specification of simplicity, the CCQ is short
(10 items) and easy to complete i.e. it is self-administered
(figure 1). It takes patients approximately 2 minutes to
complete the questionnaire, and assistance is generally
not required. Patients are instructed to recall their experi-
ences during the previous week. A 24 hours version is also
available. They respond to each question using a 7-point
scale from 0 = asymptomatic/no limitation to 6 = ex-
tremely symptomatic/totally limited. The overall clinical
COPD control score and the scores of the domains are cal-
culated by adding all the scores together and dividing this
sum by the number of questions. Thus, the overall clinical
COPD control score as well as the score on each of the
three domains varies between 0 (very good control) to 6
(extremely poor control).
Validation
Subjects
Data were collected from a study on the validation of the
CCQ and a study on stopping smoking in subjects with
and without COPD. Subjects were enrolled from notices
in the local media, from general practice and from the
outpatient clinic. All subjects were current smokers or had
a history of smoking. The studies were approved by the
Medical Ethics Committee of the University Hospital Gro-
ningen. All patients gave their written informed consent.
Individuals were defined as healthy smokers if signs of air-
way obstruction and chronic symptoms of cough and spu-
tum production were absent. In total the data of 119
(58% males) subjects were collected. Their median age
was 54 years (range 42–74) and FEV1%predicted was 88
(range 22–132). Table 1 shows the characteristics of the
study population. According to the GOLD criteria 44 were
healthy (ex)smokers (37%), 18 subjects were at risk for
COPD (15%) and 57 subjects had COPD (48%). Severity
of COPD in the latter group was as follows: 15 with mild
COPD (stage I), 36 moderate COPD (20 stage IIA, 16
stage IIB) and 6 severe COPD (stage III).
Methods
Cross-sectional validity
The Clinical COPD Questionnaire (CCQ) was adminis-
tered to all subjects. Lung function (FEV1 and FVC) was
measured according to the ERS guidelines [1] using dry
wedge spirometry (Masterscope, Jaeger, Breda, The Neth-
erlands) or using a turbine portable spirometer (Micro-
medical Microlab 3300, Sensormedics BV England). The
36 item Short Form Health Survey (SF-36), a generic
health-related quality of life questionnaire [14], was ad-
ministered to 49 participants with and without COPD.
The St George Respiratory Questionnaire (SGRQ), a dis-
ease-specific health-related quality of life questionnaire
[4], was administered to 37 patients with COPD (stage I-
III).Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/13
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Longitudinal validity
Test-retest reliability
In a subgroup of 20 subjects (15 males; median age 65
years (range 42–74); median FEV1%pred 55 (range 22–
105)) the CCQ was readministered after two weeks. At the
second visit subjects rated their perception of change in
their state of health in comparison with the previous visit,
using the global rating of change.
Figure 1
CCQ questionnaire Calculation of scores: CCQ total score = (item 1 + 2 + 3 + 4 + 5 + 6 + 7 + 8 + 9 + 10)/10; Symptom = 
(item 1 + 2 + 5 + 6)/4; Functional state = (item 7 + 8 + 9 + 10)/4; Mental state = (item 3 + 4)/2
© The Clinical COPD Questionnaire is copyrighted. It may not be changed, translated or sold (paper or
software) without permission of Thys van der Molen
CLINICAL COPD QUESTIONNAIRE
Please circle the number of the response that best describes how you have been feeling during the past week.
(Only one response for each question). 
On average, during the past week,
how often did you feel:
1. Short of breath at rest?
2. Short of breath doing physical
Activities?
3. Concerned about getting a 
 cold or your breathing getting 
 worse?
4. Depressed (down) because of
your breathing problems?
In general, during the past week, how 
much of the time:
5. Did  you cough?
6. Did  you produce phlegm?
On average, during the past 
week, how limited were you
in these activities because of 
your breathing problems:
7. Strenuous physical activities
  (such as climbing stairs,
   hurrying, doing sports)?
8. Moderate physical activities
 (such as walking,  housework,
 carrying things)?
9. Daily activities at home
 (such as dressing,  washing 
yourself)?
10. Social activities
  (such as talking, being with 
   children, visiting friends/
relatives)?
never
0
0
0
0
0
0
not limited at 
all
0
0
0
0
hardly
ever
1
1
1
1
1
1
very
slightly
limited
1
1
1
1
a few
times
2
2
2
2
2
2
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limited
2
2
2
2
several
times
3
3
3
3
3
3
moderately
limited
3
3
3
3
Many
Times
4
4
4
4
4
4
very
limited
4
4
4
4
a great 
many times
5
5
5
5
5
5
extremely
limited
5
5
5
5
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all the 
time
6
6
6
6
6
6
totally
limited /or 
unable to do 
6
6
6
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Responsiveness
In thirty-six subjects who successfully quit smoking (ob-
jectified by cotinine measurements in urine) the CCQ and
SGRQ were readministered after a period of two months
successful smoking cessation. The group consisted of 19
healthy smokers (9 males; median age 50 years (range 45–
59); median FEV1%pred 104 (range 78–128) and 17 pa-
tients at risk for/with COPD (8 males; median age 52
years (range 46–67); median FEV1%pred 75 (range 33–
107)).
Statistical Analysis
Data analysis was performed using SPSS version 9.0 (SPSS
Inc, USA). Data are expressed as medians (range) unless
stated otherwise. Internal consistency of the CCQ was
evaluated by determining the Cronbach's α coefficient
(for the three domains and the total questionnaire). Non
parametrical testing (Mann-Whitney U test) was used to
determine the discriminant validity of the CCQ to differ-
entiate among healthy (ex) smokers, patients with COPD
(stages 0 to III). Spearman's rank correlations were used to
examine convergent (HRQoL) and divergent (lung func-
tion) validity. Test-retest reliability analysis was done by
calculating the Intraclass Correlation Coefficient (ICC).
Responsiveness was tested using the Wilcoxon U test. A p
value < 0.05 was considered as statistically significant. A
priori assumptions of the relations between the CCQ and
convergent and divergent measures were made by the re-
search team in advance of the validation study
Results
Score distributions
The total score and the score on the symptom domain of
the CCQ were normally distributed. The distributions for
the domains functional and mental state were skewed. In
the whole study population fourteen subjects (12%)
scored optimal ( = 0) in the functional state domain,
whereas seventy subjects (59%) scored optimally in the
mental state domain.
Within the COPD group (stage I-III), 9 % of the patients
scored optimally in the functional state domain, whereas
47 % scored optimally in the mental state domain.
Internal consistency
Cronbach's α was 0.91 for the total score. Internal consist-
encies of the symptom, functional state and mental state
domain were 0.78, 0.89 and 0.80, respectively.
Discriminant validity
Table 2 shows that healthy (ex) smokers had significantly
different CCQ scores than patients with or at risk for
COPD. Except for the mental domain score, subjects at
risk for COPD scored significantly higher (worse) on the
CCQ as compared to the healthy (ex)smokers. Significant
differences in the CCQ scores were found between the dif-
ferent disease severity stages of COPD. The symptom do-
main score in patients with moderate COPD (stage IIB)
was significantly higher than in patients with mild COPD
(stage I) (p = 0.04). The functional state score in patients
with moderate and severe COPD was significantly higher
than in patients with mild COPD (p = 0.007, p = 0.006
and p = 0.001 for stages IIA, IIB, and III respectively). Pa-
tients with severe COPD scored significantly worse on the
functional state domain than patients with stage IIA and
IIB moderate COPD (p = 0.09 and p = 0.04 respectively).
The mental state domain score in patients with moderate
and severe COPD (stage IIB and III) was significantly
higher than in patients with mild COPD (p = 0.001 and p
= 0.04, respectively).
The total CCQ score in patients with moderate to severe
COPD (stage IIB and III) was significantly higher than in
patients with mild COPD (p = 0.006 and p = 0.003, re-
Table 1: Characteristics of the study population (n = 119)
COPD
Healthy (ex)smokers At Risk (Stage 0) Mild (Stage I) Moderate (Stage IIA) Moderate (Stage IIB) Severe (Stage III)
N4 4 1 8 1 5 2 0 1 6 6
Males (%) 48 33 60 70 81 100
Age, yr 51 (45–71) 53 (42–61) 54 (48–66) 57 (46–73) 66 (49–74) 59 (53–69)
Pack yr 24 (4–66) 29 (2–67) 31 (20–77) 35 (15–77) 36 (10–85) 34 (12–45)
Current 
smoking(%)
89 100 100 85 75 83
FEV1 (%pred) 101 (62–128) 105 (82–132) 93 (81–116) 69 (51–75) 41 (30–49) 24 (22–28)
Healthy (ex) smokers; normal spirometry, no chronic symptoms (cough, sputum production). COPD classification of COPD by severity according 
to the GOLD guidelines; Stage 0: normal spirometry, chronic symptoms (cough, sputum production); Stage I: FEV1/FVC < 70%, FEV1 ≥ 80 % pre-
dicted, with or without chronic symptoms (cough, sputum production, dyspnea); Stage IIA: FEV1/FVC < 70%, 50% ≥ FEV1 < 80 % predicted; Stage 
IIB: FEV1/FVC < 70%, 30% ≥ FEV1 < 50 % predicted; Stage III: FEV1/FVC < 70%, FEV1 < 30 % predicted or FEV1 < 50% predicted plus respiratory fail-
ure or clinical signs of right heart failure.Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/13
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spectively). Patients with severe COPD scored
significantly higher than patients with moderate COPD
(stage IIA) (p = 0.028).
Convergent validity
CCQ and SF-36
The CCQ score showed significant correlations with all
but the pain component of the SF-36 (table 3). The CCQ
score was strongly related with the physical functioning
component of the SF-36 (ρ = 0.69: p < 0.01).
CCQ and SGRQ
Table 4 shows correlations between the CCQ score and
the SGRQ scores. The total scores of both questionnaires
were significantly correlated (ρ = 0.72; p < 0.01). The
symptom domain of the CCQ correlated significantly
with the symptom component of the SGRQ (ρ = 0.75; p <
0.01). The functional state domain of the CCQ correlated
strongly with the activity component of the SGRQ (ρ =
0.69; p < 0.01).
Divergent validity
CCQ and lung function
The CCQ scores and FEV1%pred correlated significantly
in patients with COPD (stage I-III), with the highest cor-
relation between the total score and FEV1 %predicted (ρ =
-0.49: p < 0.01) (figure 2). The correlation was ρ = -0.38
(p < 0.01) in the total group, which included patients at
risk for COPD and healthy (ex)smokers.
Test-retest reliability
The intraclass correlation coefficient was 0.94 for the total
CCQ score.
Table 2: CCQ scores in subgroups (Healthy, At Risk and COPD (Stage I-III))
COPD
CCQ Healthy (ex)smokers At Risk (Stage 0) Mild (Stage I) Moderate A(Stage IIA) Moderate B (Stage IIB) Severe (Stage III)
Symptom 1.5a  3.3b  1.8a,c  2.0c,d  3.1b,d  2.9,b,c 
(0.3–3.5) (1.8–5.3) (0.5–5.0) (0.8–5.3) (0.8–4.5) (1.5–4.5)
Functional 0.8a  1.4b,c  0.3a  1.4b  1.5b  2.6c 
state (0.0–3.8) (0.3–6.0) (0.0–2.5) (0.3–4.0) (0.5–4.8) (2.0–5.0)
Mental state 0.0a  0.0a,b  0.0a  0.0a,c  1.0b  0.5b,c 
(0.0–3.0) (0.0–3.5) (0.0–1.0) (0.0–4.5) (0.0–5.0) (0.0–3.0)
Total 0.8a  2.0b,c  1.0a,d  1.3b,d  1.9b,c  2.5c
(0.1–3.3) (0.8–5.2) (0.2–2.5) (0.5–4.3) (0.9–4.7) (1.7–4.3)
CCQ = Clinical COPD Questionnaire; range 0 – 6; 0 indicating best possible clinical control and 6 indicating worst possible clinical control. Medians 
not sharing a common superscript letter (a,b,c,d) are significant different at p < 0.05 after Mann-Whitney U test. Healthy (ex) smokers; normal 
spirometry, no chronic symptoms (cough, sputum production). COPD classification of COPD by severity according to the GOLD guidelines; Stage 
0: normal spirometry, chronic symptoms (cough, sputum production); Stage I: FEV1/FVC < 70%, FEV1 ≥ 80 % predicted, with or without chronic 
symptoms (cough, sputum production, dyspnea); Stage IIA: FEV1/FVC < 70%, 50% ≥ FEV1 < 80 % predicted; Stage IIB: FEV1/FVC < 70%, 30% ≥ FEV1 
< 50 % predicted; Stage III: FEV1/FVC < 70%, FEV1 < 30 % predicted or FEV1 < 50% predicted plus respiratory failure or clinical signs of right heart 
failure.
Table 3: Correlations between CCQ with SF-36 in healthy (ex)smokers and patients at risk for/with COPD (n = 49)
Clinical COPD Questionnaire
Symptom Functional state Mental state Total
SF-36
Physical functioning -0.54** -0.70** -0.65 ** -0.69**
Social functioning -0.45** -0.49** -0.34* -0.49**
Role physical -0.46** -0.52** -0.47** -0.53**
Role emotional -0.45** -0.50** -0.36* -0.48**
Mental health -0.40** -0.48** -0.34* -0.49**
Vitality -0.52** -0.55** -0.27 -0.58**
Pain -0.22 -0.26 -0.17 -0.26
Health perceptions -0.49** -0.54** -0.40** -0.56**
SF-36 = Medical Outcome Survey Short Form-36 (higher score indicates better health status); * P < 0.05; ** P < 0.01, Spearman's rank correlation.Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/13
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Responsiveness
Results of the responsiveness to change of the CCQ, as
tested in the smoking cessation group, are shown in table
5. The CCQ significantly improved after two months
smoking cessation. The total score of the SGRQ showed
no significant changes.
Discussion
In this study we developed and validated a questionnaire
to measure clinical control in patients with COPD, the
Clinical COPD Questionnaire (CCQ). To our knowledge
this is the first questionnaire specifically developed and
validated to measure clinical success in the management
of patients with COPD. The items were generated by liter-
ature search, clinicians and patients. Items were thereafter
selected on their clinical importance by the world leading
clinical experts in this area. Results show that the ques-
tionnaire is valid, reliable and promises to be responsive
to changes in patients with all stages of COPD.
Development
We used established psychometric methods to develop
the CCQ [12]. In the first phase, a large pool of relevant
items was generated. This phase included in-depth inter-
views with patients, patient focus group discussions, dis-
cussions with health care professionals and a review of the
literature on other COPD questionnaires. In the second
phase, international experts were recruited to identify the
questions that should be included based on their clinical
relevance. The high response rate (87%) gives an indica-
tion of the perceived importance to develop such a ques-
tionnaire. Clinicians were chosen to assist in the final item
selection in order to develop a questionnaire that reflects
the items that are considered important to measure treat-
ment success in patients with COPD in day-to-day clinical
practice. As a consequence, items as wheezing, fatigue,
shortness of breath at night or due to emotional distress,
fear, bad mood and cognition were excluded from the fi-
nal questionnaire based on the importance and ranking
score of the clinicians.
Validation
Although the CCQ has mainly been developed for evalu-
ative purposes, this study shows that the CCQ also has
strong discriminative measurement properties and can be
used in all patients with COPD including patients in
group 0 according to GOLD guidelines. The CCQ has
been developed to measure clinical disease control, i.e.
specific disease-related consequences, like symptoms and
consequences on functional and mental state, the full
range of clinical impairment, as indicated by patients and
clinicians. The CCQ is not intended to assess patients
well-being or the impact of the disease on patients' well-
being, and therefore the CCQ is not a tool to measure
health related quality of life. In contrast, health related
quality of life instruments are measuring issues such as the
impact of symptoms on health related quality of life.
Therefore, the SF36 and the St George Respiratory Ques-
tionnaire have been used in the validation process as
instruments to measure convergent validity. Moderate to
high correlations between the CCQ and the SF-36 and
SGRQ were found, supporting the convergent validity.
The total score on the CCQ was highly correlated to the to-
tal score on the SGRQ.
Lung function was used to measure divergent validity. As
expected, the correlation between the CCQ and lung func-
tion measurement is lower (divergent validity). However,
quite surprisingly, the relation between the FEV1% pre-
dicted and the total score of the CCQ in patients with
COPD was rather high (-0.49) as compared to a priori as-
sumptions (-0.20 to -0.40). The relation between the CCQ
on one hand and lung function on the other hand seems
to be stronger than presumed by the investigators in the
first stage of this project. This finding is limited to the
group of patients with stage I-III COPD as measured by
airway obstruction. The CCQ scores of the total group of
participants were less strongly related to FEV1% predicted.
This may be due to the high predominance of symptoms
in subjects at risk for COPD (normal spirometry and
chronic symptoms).
Table 4: Correlations between CCQ and SGRQ in patients with COPD (n = 38)
Clinical COPD Questionnaire
Symptom Functional state Mental state Total
SGRQ
Symptoms 0.75** 0.49** 0.60** 0.72**
Activity 0.25 0.69** 0.52** 0.53**
Impact 0.47** 0.69** 0.61** 0.67**
Total 0.51** 0.75** 0.67** 0.71**
SGRQ = St. George Respiratory Questionnaire (higher score indicates worse HRQOL) * P < 0.05; ** P < 0.01, Spearman's rank correlation.Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/13
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Figure 2
Correlation between CCQ and FEV1 %predicted in patients with COPD (n = 58) CCQ = Clinical COPD 
Questionnaire
Table 5: Changes of CCQ and SGRQ scores in subjects who successful quitted smoking fortwo months (n = 36)
Baseline 2 months SC p value
CCQ
Healthy smokers (n = 19) 0.6 (0.1–2.1) 0.3 (0.0–1.6) * 0.012
GOLD (0-III) (n = 17) 1.5 (0.5–4.7) 1.0 (0.2–3.0) * 0.035
SGRQ
GOLD (0-III) (n = 12) 27.0 (8.1–62.4) 23.9 (6.3–53.1) 0.433
SGRQ = St. George Respiratory Questionnaire. SC = smoking cessation. * p < 0.05. Wilcoxon U test.
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A considerable proportion (37%) of subjects was includ-
ed who smoked or had smoked yet did not have airway
obstruction and chronic symptoms like cough and spu-
tum production. Although we used the term healthy (ex)
smokers to indicate these subjects without airway obstruc-
tion and chronic symptoms, CCQ scores revealed the
presence of respiratory symptoms in these subjects. This
finding supports the idea that smokers without chronic
symptoms are at risk for developing transient COPD-like
symptoms. The CCQ seems to be sensitive enough to de-
tect these early symptoms.
To our surprise, CCQ scores were high in subjects at risk
for COPD (GOLD stage 0). This finding may be very im-
portant for normal daily clinical practice. The GOLD
guidelines refer to this group as being at risk for develop-
ing COPD (stage 0) and recommend the reduction of risk
factors as single focus of therapy. It seems that this group
of patients with normal lung function but with chronic
symptoms report the same level of clinical control as a
group of patients with moderate to severe COPD
(FEV1%pred < 50). Subjects at risk for COPD will com-
monly be treated by the general practitioner, but without
proper evidence-based background about how to treat
these patients except for the provision of smoking cessa-
tion advice and support. It may well be that the CCQ
could also be used for research and clinical purposes in
these subjects at risk for COPD. The current study shows
that the CCQ can be used to evaluate interventions in pa-
tients with COPD and in healthy smokers. Whether the
CCQ might be used to motivate individual patients to
quit smoking needs to be investigated.
In patients with COPD defined by the presence of airway
obstruction (GOLD stage I-III), the CCQ was able to
detect differences in disease severity. Patients with mild
disease had a better control of their disease than patients
with moderate disease (stage IIB), as defined by level of
lung function. This is in agreement with an earlier finding
of Jones and colleagues [15], sharing that once the FEV1
falls below 50% of predicted restrictions to essential activ-
ities of daily living become more apparent.
Responsiveness
Longitudinal data of 36 subjects who successfully quit
smoking for two months showed clear improvement on
the CCQ. The medical ethical committee did not allow to
follow up those patients who were not successful in
quitting smoking, thus preventing the comparison be-
tween data from individuals who were successful and un-
successful in quitting smoking. Smoking cessation is the
most effective therapeutic intervention in patients with
COPD [7]. Kanner et al. showed a clear difference in de-
cline in lung function and number of lower respiratory
tract infections between smokers and sustained quitters in
a 5 year follow-up study [16]. In our study the CCQ shows
significant improvement after two months smoking cessa-
tion while scores on the SGRQ, although in the same di-
rection, did not reach statistical significance. The CCQ
improvement by smoking cessation was not limited to pa-
tients with COPD. Even healthy smokers without chronic
symptoms but with a baseline score of 0.6 on the CCQ
showed a statistically significant improvement after two
months of smoking cessation. Smoking cessation had a
positive effect on the variables as defined by the CCQ in a
relatively short space of time and showed to be more use-
ful than the SGRQ since its recall time is one year. Further-
more, the SGRQ is not appropriate to be used in healthy
smokers.
In summary, the validation of the questionnaire shows
strong discriminative properties, test-retest reliability and
responsiveness. Although the CCQ has been developed
for use in patients with COPD, this study demonstrated
that the questionnaire can also be used in patients at risk
for COPD (group 0 according to GOLD guidelines). Fur-
thermore, the validation study showed that the CCQ is
very sensitive for clinical improvement after smoking ces-
sation. We therefore believe that there is an important role
for the CCQ in clinical practice as well as in clinical trials.
The CCQ is able to identify patients with poor clinical
COPD control and will also be able, more accurately than
recall, to evaluate the effect of interventions in a standard-
ized way.
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